Biotech and healthtech have the richest government grant landscape of any sector. NIH alone distributes roughly $1.2 billion in SBIR funding annually across 27 institutes. Add ARPA-H, BARDA, state programs, and NSF, and the total available funding for health-related startups exceeds $2 billion per year. No other sector comes close.
But the landscape is also the most complex. Picking the wrong NIH institute can mean the difference between a 40% and 15% funding probability. ARPA-H and NIH look similar on paper but operate completely differently. BARDA only funds health security, not general healthtech. And the registration requirements (SAM.gov, eRA Commons, SBA) can take 6-8 weeks if you don't start early.
This guide maps every federal program that funds biotech and healthtech startups -- with the strategic details that actually affect whether you win.
The biotech grant landscape at a glance
| Program | Phase I | Phase II | Best For | Review Style | Speed |
|---|---|---|---|---|---|
| NIH SBIR | $314K | $2.1M | Therapeutics, diagnostics, devices, clinical AI | Peer panel (study section) | 6-9 months |
| ARPA-H | $600K | $3.5M | Health moonshots, 10x breakthroughs | PM-directed | Varies |
| BARDA DRIVe | $50K-$750K | Up to $20M | Pandemic prep, diagnostics, antivirals, biodefense | Rolling EZ-BAA | Fast (weeks) |
| NSF SBIR | $305K | $1.25M | Biotech with technology focus, bioengineering | Peer panel + pitch step | 4-6 months |
| DOD SBIR | $75K-$256K | $1.25M-$1.7M | Military medicine, battlefield health | Topic-based | 2-6 months |
| State programs | $100K-$750K | Varies | State-specific biotech ecosystems | Varies | 1-6 months |
NIH SBIR: the backbone of biotech grant funding
NIH is where most biotech and healthtech startups should start. Each of NIH's 27 Institutes and Centers runs its own SBIR program with its own disease focus, budget, and -- critically -- its own funding threshold.
Award amounts
- Phase I: Up to $314,363 (the SBA cap; 6-24 months)
- Phase II: Up to $2,095,748 (1-3 years)
- Commercialization Readiness Pilot (CRP): Up to $4,191,495 (3 years)
- Direct-to-Phase-II: Available for companies with existing feasibility data
Individual institutes may set lower budget caps than the SBA maximum. Check the specific IC's guidelines before budgeting at the cap.
Which institute funds what
This is the most important strategic decision in your NIH application. Your technology must match the institute's mission -- a heart device sent to the National Eye Institute gets an instant rejection.
| Institute | Abbreviation | What They Fund | SBIR Payline |
|---|---|---|---|
| National Cancer Institute | NCI | Cancer diagnostics, therapeutics, imaging, prevention | ~27 |
| National Institute of Allergy and Infectious Diseases | NIAID | Infectious disease, vaccines, antimicrobials, immunology | 29 |
| National Heart, Lung, and Blood Institute | NHLBI | Cardiovascular devices, pulmonary diagnostics, blood disorders | 30 |
| National Institute of Mental Health | NIMH | Mental health diagnostics, digital therapeutics, neuroimaging | <40 |
| National Institute on Aging | NIA | Alzheimer's, aging, gerontechnology, age-related disease | <34 (up to 45) |
| National Institute of Diabetes and Digestive and Kidney Diseases | NIDDK | Diabetes devices, GI, kidney, metabolic disorders | ~25 |
| National Institute of General Medical Sciences | NIGMS | Sepsis, pharmacology, cell biology, biophysics, biomedical technology | ~28 |
| National Institute of Biomedical Imaging and Bioengineering | NIBIB | Medical imaging, biosensors, point-of-care diagnostics, wearables | ~30 |
| National Center for Advancing Translational Sciences | NCATS | Drug repurposing, rare diseases, clinical trial innovation | ~30 |
The payline is your probability filter. SBIR applications are scored on a 1-9 scale (1 is best). Only applications scoring below the payline get funded. A score of 30 gets funded at NIMH, NIA, and NHLBI -- but gets rejected at NIDDK.
This means: if your technology spans multiple disease areas, the institute you choose can materially affect your odds. A digital health platform that addresses both aging and diabetes could be submitted to NIA (payline <34) instead of NIDDK (payline ~25). Same technology, dramatically different funding probability.
How to pick the right institute
- Start with mission fit. Which institute's disease area does your technology serve?
- Contact a Program Officer. Share a 1-page concept paper or Specific Aims page. POs are subject-matter experts who will tell you whether your project fits their mission, suggest alternative ICs, and sometimes flag upcoming priority topics.
- If you're unsure, email the NIH SEED Office -- they'll direct you to the right PO.
- Consider payline strategy. If your technology genuinely spans multiple ICs, choose the one with the more generous payline. This is legitimate and common among experienced applicants.
NIH SBIR quirks that matter
Preliminary data is critical. Unlike NSF (which doesn't require preliminary data), NIH reviewers expect evidence that your approach works. First-time applicants with no data face significantly steeper odds. Even a small pilot study or in vitro result strengthens your application materially.
The Omnibus Solicitation is the primary entry point. Three review cycles per year with fixed deadlines. You propose your own idea (no topic matching required), though each IC publishes topics of interest.
PI citizenship is NOT required. Non-US citizens can serve as PI on NIH SBIR, unlike some other agencies.
STTR is the academic spinout path. If you're spinning out of a university and want to keep your faculty appointment, STTR (Small Technology Transfer Research) lets a university PI serve as co-PI while the startup is the lead applicant. STTR requires a formal subcontract with the research institution (at least 30% of the work). Same award amounts as SBIR. This is the standard path for lab-to-startup transitions.
Study sections include industry reviewers. Applications are reviewed by panels that include researchers, academics, and required industry representatives. About 50% of applications are scored; the rest receive "Not Discussed" (triaged) with no detailed feedback.
For more on NIH scoring, see our guide to how SBIR applications are scored.
ARPA-H: health moonshots with bigger checks
ARPA-H was launched in 2022 as NIH's more aggressive sibling. Where NIH funds proven scientific approaches through peer review, ARPA-H funds breakthrough health technology through program manager-directed investments.
How ARPA-H differs from NIH
| Dimension | NIH SBIR | ARPA-H |
|---|---|---|
| Review model | Peer panel (study section) | Program Manager directed |
| Innovation bar | Incremental advances welcome | 10x improvement required |
| Phase I cap | $314,363 | $600,000 |
| Phase II cap | $2,095,748 | $3,500,000 |
| Non-SBIR awards | Limited | Up to $50M+ per performer |
| Application style | Standard proposal | Solution Summary → full proposal |
| Speed | 6-9 month review | Varies (can be faster) |
| Feedback | Summary statement with scores | Direct PM engagement |
ARPA-H mission offices
ARPA-H organizes funding through four mission offices, each accepting rolling Innovative Solution Openings (ISOs):
- Health Science Futures: Removing scientific and technological barriers to future healthcare
- Proactive Health: Preventive programs that keep people from becoming patients
- Resilient Systems: Building robust, integrated healthcare systems
- Scalable Solutions: Addressing geography, manufacturing, data, and equity challenges
Current ARPA-H programs (2026)
- ADVOCATE: Agentic AI for 24/7 cardiovascular disease management
- AIR: Autonomous surgical systems and micro-scale medical robotics
- MOCS: Maternal care technology -- placental testing, wireless fetal sensors, AI-backed monitoring
- BoSS: BioStabilization Systems for medical logistics
Who should apply to ARPA-H vs. NIH: If your technology could fundamentally change how a disease is detected, treated, or prevented -- at a scale or speed that doesn't exist today -- ARPA-H is the right fit. If you're improving an existing diagnostic by 20% accuracy or developing a next-generation drug delivery system, NIH is where you belong. The 10x bar at ARPA-H is real, and program managers reject ideas that feel incremental.
BARDA DRIVe: fast funding for health security technology
BARDA DRIVe is the venture arm of the Biomedical Advanced Research and Development Authority. It's narrower than NIH or ARPA-H -- focused specifically on health security threats -- but it's one of the fastest federal funding paths for startups in its lane.
What BARDA DRIVe funds
- Novel pathogen detection and diagnostics
- Broad-spectrum antivirals (the VITAL Hub committed $100M)
- Antimicrobial resistance solutions
- Pandemic preparedness technology
- Digital health tools for health security readiness
- Pediatric medical countermeasures
Funding mechanisms
EZ-BAA (Simplified Broad Agency Announcement): Rolling submissions, up to $750,000. This is the fastest entry point -- simplified application, no fixed deadline.
Accelerator Network: Milestone-based programs through partner hubs:
- $50K-$200K per project, 4-12 week durations
- Programs include I-CREATE, VANGUARD, SPARK DEV
- Focus on early validation and rapid prototyping
Full awards: Up to $20M for programs advancing through BARDA's pipeline.
Who should apply: If your technology addresses pandemic preparedness, biodefense, novel diagnostics for emerging pathogens, or antimicrobial resistance, BARDA DRIVe's EZ-BAA should be on your list. If your healthtech is focused on chronic disease, wellness, or general clinical workflows, BARDA isn't the right fit -- try NIH or NSF instead.
NSF SBIR: biotech with a technology angle
NSF SBIR covers biotechnology under its broader science and engineering umbrella. Phase I awards $305,000, Phase II up to $1.25M. The advantage: rolling submissions via a 4-page Project Pitch, no preliminary data required, and faster turnaround than NIH.
When NSF beats NIH for biotech:
- Your innovation is in the technology (novel biosensor platform, new bioprocessing method) rather than a specific disease application
- You don't have preliminary data yet (NSF doesn't require it; NIH practically does)
- You want faster feedback (3-week pitch review vs. 6-9 month NIH cycle)
- Your technology spans biotech and another domain (AI, materials science, engineering)
When NIH is better:
- Your technology is disease-specific and you have preliminary data
- You need the larger Phase II amount ($2.1M vs. $1.25M)
- NIH's brand carries more weight in your fundraising or regulatory path
Many biotech startups apply to both NSF and NIH with different proposals emphasizing different aspects of the same technology. This is legitimate and common.
FDA accelerators: not grants, but critical for healthtech
These aren't funding programs, but they materially affect your timeline and fundraising -- and investors care about them.
Breakthrough Device Designation
As of late 2025, FDA has granted over 1,200 Breakthrough Device designations. About 40% of applicants receive it. Benefits: priority review, direct access to FDA reviewers, faster decision timelines. The designation itself is a strong signal to investors -- it means FDA considers your device to address an unmet need with a potentially significant advantage.
TAP (Total Product Life Cycle Advisory Program)
Launched in 2023 for Breakthrough-designated devices. Provides direct access to a lead reviewer, written feedback within 21-40 days, and early discussions with FDA, payors, and physicians simultaneously. At least one participating company saved a full year of development time. Currently covers cardiovascular, neurological, radiological, ophthalmology, and orthopedic devices.
Pre-Submission (Q-Sub) Program
Free meetings with FDA to discuss regulatory strategy before formal submission. Available to any company -- no special designation needed. The most underused resource in healthtech. Request a pre-sub meeting before you write your SBIR proposal -- it strengthens both your regulatory strategy and your grant application.
State programs for biotech startups
Several states have dedicated biotech funding beyond federal programs.
MassVentures START (Massachusetts): $100K-$500K in non-dilutive grants for companies that receive a Phase II SBIR/STTR award. Covers marketing, business development, and IP strategy -- activities that federal grants don't fund. 26 companies received $4.5M in 2025.
Massachusetts Life Sciences Center (MLSC): $700M+ deployed to date. Current programs include Bits to Bytes ($750K for large dataset projects), Frontiers Fund ($200K+ for early translational research), and Novel Therapeutics Delivery ($750K).
CIRM (California Institute for Regenerative Medicine): $8.5B state-funded agency for stem cell and gene therapy. The first FDA-approved CIRM-funded therapy was approved in 2026 (Rocket Pharmaceuticals). Primarily funds academic institutions but for-profit companies can access translational and clinical programs.
SBIR matching programs: Several states match federal SBIR awards dollar-for-dollar, effectively doubling your Phase I. Check your state's SBIR support office.
AHRQ: a niche path for health IT
AHRQ (Agency for Healthcare Research and Quality) runs an R21/R33 program for digital healthcare solutions -- AI, data analytics, interoperability, patient engagement, and remote monitoring. R21 awards $280K over 2 years; R33 awards $720K over 3 years.
Critical catch: AHRQ requires the lead applicant to be a US-based public or nonprofit institution. For-profit startups can only participate as subawardees or consortium partners. You'd need a hospital or university partner as the prime applicant. This limits its utility for most startups, but if you have an academic collaborator, it's worth exploring.
The NIH registration gauntlet
First-time NIH applicants face a multi-step registration process that can take 6-8 weeks. Start this immediately -- before you write a single word of your proposal.
- SAM.gov registration (2-4 weeks) -- Required for all federal grants. Includes getting a UEI (Unique Entity Identifier).
- eRA Commons registration (1-2 weeks) -- NIH's grants management system. Both the organization and the PI need accounts.
- SBA Company Registry (1-2 weeks) -- Certifies your small business status for SBIR eligibility.
- Grants.gov registration (1 week) -- Federal grants submission portal.
NIH considers starting eRA Commons registration at least 10 business days before a deadline a "good faith effort." If NIH-caused delays make you miss the deadline, late submission may be permitted. But don't rely on this -- start early.
Stacking strategy by stage
Pre-seed (spinning out of a lab)
- NSF SBIR Project Pitch -- fastest entry, no preliminary data needed, $305K
- NIH SBIR Phase I at the institute matching your disease area -- use your academic data as preliminary evidence
- State grants -- MassVentures START, MLSC, CIRM if eligible
- Potential non-dilutive stack: $300K-$800K before any equity round
Seed (first customers or clinical evidence)
- NIH SBIR Phase I ($314K) with stronger preliminary data
- BARDA DRIVe EZ-BAA if health security angle ($750K, rolling)
- ARPA-H ISO if your technology is genuinely breakthrough
- FDA Breakthrough Device designation (not funding, but strengthens investor pitch)
- Potential stack: $500K-$1.5M non-dilutive alongside seed equity
Series A (product-market fit, regulatory pathway clear)
- NIH SBIR Phase II ($2.1M) using Phase I results
- ARPA-H full program participation (up to $50M+ for breakthrough platforms)
- BARDA full awards (up to $20M for health security products advancing through pipeline)
- State matching programs (dollar-for-dollar on federal SBIR)
- Potential stack: $2M-$5M+ non-dilutive alongside Series A equity
At every stage, grant funding does double duty: it funds R&D and provides the technical validation that helps you raise stronger equity rounds.
Biotech SBIR success stories
The program's track record in biotech is long and well-documented:
- Moderna -- NIH SBIR funded early mRNA delivery research. Market cap reached $100B+ during COVID vaccine rollout.
- 23andMe -- SBIR-funded for about a decade. CEO Anne Wojcicki said SBIR funding had a "powerful validating effect." Went public at $3.5B valuation.
- Illumina -- NCI SBIR funded core next-generation sequencing technology. Now a $30B+ market cap company.
- Genzyme -- Early SBIR recipient, acquired by Sanofi for $20B.
Across the full program, NIH SBIR/STTR has supported 99 drugs and brought over 700 life-saving products to market over 25 years.
The bottom line
Biotech and healthtech startups have the deepest federal grant landscape of any sector. NIH's 27 institutes provide multiple entry points with awards up to $2.1M. ARPA-H raises the ceiling to $3.5M (SBIR) or $50M+ (non-SBIR) for genuine breakthroughs. BARDA DRIVe offers fast rolling funding for health security technology.
The founders who capture the most funding don't just apply to "NIH." They match their technology to the right institute, understand the payline differences, time their applications with the three annual cycles, and stack federal grants with state programs and FDA designations to build a comprehensive non-dilutive portfolio.
Want to know which health programs fit your specific technology?
The institute you pick, the program you target, and how you frame your innovation for reviewers can be the difference between funded and triaged. We've written 500+ proposals across NIH, ARPA-H, BARDA, and NSF -- including health AI, diagnostics, therapeutics, and medical devices. Our Strategy Review identifies the programs where your healthtech startup has the strongest shot.